Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Dicerna Pharmaceuticals
Biotech
JPM23: After rock climbing in biotech, Novartis' CMO is back
Novartis' Shreeram Aradhye is back after time in biotech, but he doesn't think the downturn offers a plethora of great assets for pharma's choosing.
Gabrielle Masson
Jan 12, 2023 6:00am
Former AbbVie R&D chief tapped to run Tessera—Chutes & Ladders
Jun 3, 2022 9:30am
Novo Nordisk bets big on RNAi, paying $3.3B to buy Dicerna
Nov 18, 2021 8:35am
Dicerna flops efficacy endpoint on nedosiran in PH2
Oct 19, 2021 9:40am
Dicerna wants partner to sell nedosiran
Aug 10, 2021 8:00am
Dicerna drops after mixed data on rival to Alnylam drug
Aug 6, 2021 8:10am
